Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Lea, sialyl Le(x), GD3 and GM2) better than soluble lysate cancer vaccine

Anti-Cancer Drugs

Volumn 8, Issue 3, 1997, Pages 217-224

  Ravindranath, Mepur H ^a   Bauer, Philip M ^a   Amiri, Amir A ^a   Miri, Seyed M ^a   Kelley, Mark C ^a   Jones, Ralph C ^b   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Bacille Calmette Guerin; cancer vaccines; carbohydrate antigens; delayed type hypersensitivity reaction; gangliosides; GD2; GD3; GM2; IgG antibodies; melanoma; sialyl Lewis(x); sialyl Lewisa

Indexed keywords

ADJUVANT; BCG VACCINE; CANCER VACCINE; CARBOHYDRATE ANTIGEN; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM1; IMMUNOGLOBULIN G; MEMBRANE ANTIGEN; TUMOR ANTIGEN; VACCINE;

ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL; CELL LINE; CELL LYSATE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; IMMUNIZATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, SURFACE; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BCG VACCINE; CANCER VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GANGLIOSIDES; GUINEA PIGS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; MELANOMA;

EID: 0030988912     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199703000-00001     Document Type: Article

References (22)

1. Morton DL, Ravindranath MH. Current concepts concerning melanoma vaccines. In: Dalgleish A, Browning H, eds. Tumor immunology. London: Cambridge University Press 1996: 241-68.
2. Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1994; 216: 463-82.
3. Wallack M, Sivandham M, Balch CM, et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75: 34-42.
4. Schirrmacher V, Hoegen PL. Importance of tumor cell membrane integrity and viability for cytotoxic T lymphocyte activation by cancer vaccines. Vaccine Res 1993; 2: 183-95.
5. Ravindranath MH, Brazeau SM, Morton DL. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside. Experientia 1994; 50: 648-53.
6. Hanai N, Shitara K, Yoshida H. Distribution of a squamous cell lung carcinoma-associated antigen, KA-32, in human tissues and sera defined by monoclonal antibody KM-32. Cancer Res 1986; 46; 5206-10.
7. Hanai N, Shitara K, Furuya A, et al. Detailed characterization of reactivities of anti-gastric cancer monoclonal antibodies to carbohydrate antigen. Anticancer Res 1990; 10: 1579-86.
8. Pukel CS, Lloyd KO, Travassos LR, et al. GD3, a prominent ganglioside of human melanoma: detection and characterization of mouse monoclonal antibody. J Exp Med 1982; 155: 1133-9.
9. 3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol 1986; 102: 688-92.
10. Ravindranath MH, Amiri AA, Bauer PM. A sensitive cell suspension ELISA [cs-ELISA] for measuring the density of cell-surface ganglioside and carbohydrate antigens. In: Townsend R, Hotchkiss A, eds. Techniques in glycobiology. New York: Marcel Dekker 1997: 137-65.
11. Ravindranath MH, Bauer PM, Cornillez-Ty C, Garcia J, Morton DL. Quantitation of the density of cell-surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA. J Immunol Methods (in press).
12. Ravindranath MH, Ravindranath RMH, Morton DL, Graves MC. Factors affecting the fine specificity and sensitivity of serum anti-ganglioside antibodies in ELISA. J Immunol Methods 1994; 169: 257-72.
13. Ravindranath MH, Irie RF. Gangliosides as antigens of human melanoma. In: Nathanson L, ed. Malignant melanoma: biology, diagnosis, and therapy. Boston, MA: Kluwer 1988: 17-42.
14. Ravindranath MH, Morton DL. Role of gangliosides in active immunotherapy with melanoma vaccine, Int Rev Immunol 1995; 7: 303-29.
15. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995; 145: 147-66.
16. Magnani JL, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastro-intestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982; 257: 14365-9.
17. a as a target for bispecific antibody-directed adoptive tumor immunotherapy. Immunol Lett 1995; 44: 35-40.
18. x-negative melanoma cell line binds to E-selectin but not to P-selectin. Cancer Res 1987; 47: 1267-72.
19. a expression and tumor progression in melanoma. Cancer Res 1995; 55: 1748-51.
20. Freimer ML, McIntosh K, Adams RA, Alving CR, Drachman DB. Gangliosides elicit a T-cell independent Ab response. J Autoimmun 1993; 6: 281-9.
21. Hardings CV, Roof RW, Allen PM, Unanue ER. Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules. Proc Natl Acad Sci USA 1991; 88: 2740-4.
22. Ishioka GY, Lamont AG, Thomson D, et al. MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol 1992; 148: 2446-51.